A possible protective role of Nrf2 in preeclampsia

Annals of Anatomy

Volumn 196, Issue 5, 2014, Pages 268-277

  Kweider, Nisreen ^a   Huppertz, Berthold ^b   Kadyrov, Mamed ^a,c   Rath, Werner ^d   Pufe, Thomas ^a   Wruck, Christoph Jan ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c MEDIAN Kliniken   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

CO; Heme oxygenase 1; Nrf2; Preeclampsia

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; CULLIN; HEME OXYGENASE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PROTEIN KINASE C; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NRF2; VASCULOTROPIN RECEPTOR 1; NFE2L2 PROTEIN, HUMAN;

ANTIOXIDANT RESPONSIVE ELEMENT; CELL PROTECTION; CYTOTROPHOBLAST; ELECTROPHILICITY; HUMAN; INNATE IMMUNITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PREECLAMPSIA; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; SYNCYTIOTROPHOBLAST; UBIQUITINATION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; ADULT; ANIMAL; FEMALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY;

ANIMALIA;

ADULT; ANIMALS; FEMALE; HEME OXYGENASE-1; HUMANS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PRE-ECLAMPSIA; PREGNANCY;

EID: 84905220825     PISSN: 09409602     EISSN: 16180402     Source Type: Journal    
DOI: 10.1016/j.aanat.2014.04.002     Document Type: Review

References (132)

1. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet. Gynecol. 2013, 122:1122-1131.
2. Alam J., Stewart D., Touchard C., Boinapally S., Choi A.M., Cook J.L. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J. Biol. Chem. 1999, 274:26071-26078.
3. Ashino T., Yamamoto M., Yoshida T., Numazawa S. Redox-sensitive transcription factor Nrf2 regulates vascular smooth muscle cell migration and neointimal hyperplasia. Arterioscler. Thromb. Vasc. Biol. 2013, 33:760-768.
4. Baba K., Morimoto H., Imaoka S. Seven in absentia homolog 2 (Siah2) protein is a regulator of NF-E2-related factor 2 (Nrf2). J. Biol. Chem. 2013, 288:18393-18405.
5. Bainbridge S.A., Smith G.N. HO in pregnancy. Free Radic. Biol. Med. 2005, 38:979-988.
6. Banday A.A., Lokhandwala M.F. Transcription factor nrf2 protects renal dopamine d1 receptor function during oxidative stress. Hypertension 2013, 62:512-517.
7. Barbagallo I., Galvano F., Frigiola A., Cappello F., Riccioni G., Murabito P., D'Orazio N., Torella M., Gazzolo D., Li Volti G. Potential therapeutic effects of natural heme oxygenase-1 inducers in cardiovascular diseases. Antioxid. Redox Signal. 2013, 18:507-521.
8. Belo L., Caslake M., Santos-Silva A., Castro E.M., Pereira-Leite L., Quintanilha A., Rebelo I. LDL size, total antioxidant status and oxidised LDL in normal human pregnancy: a longitudinal study. Atherosclerosis 2004, 177:391-399.
9. Bilban M., Haslinger P., Prast J., Klinglmuller F., Woelfel T., Haider S., Sachs A., Otterbein L.E., Desoye G., Hiden U., Wagner O., Knofler M. Identification of novel trophoblast invasion-related genes: heme oxygenase-1 controls motility via peroxisome proliferator-activated receptor gamma. Endocrinology 2009, 150:1000-1013.
10. Brown M.C., Best K.E., Pearce M.S., Waugh J., Robson S.C., Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur. J. Epidemiol. 2013, 28:1-19.
11. Bryan H.K., Olayanju A., Goldring C.E., Park B.K. The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem. Pharmacol. 2013, 85:705-717.
12. Burton G.J. Oxygen, the Janus gas; its effects on human placental development and function. J. Anat. 2009, 215:27-35.
13. Burton G.J., Jauniaux E. Oxidative stress. Best practice & research. Clin. Obstet. Gynaecol. 2011, 25:287-299.
14. Burton G.J., Yung H.W. Endoplasmic reticulum stress in the pathogenesis of early-onset pre-eclampsia. Pregnancy Hypertens. 2011, 1:72-78.
15. Chamy V.M., Lepe J., Catalan A., Retamal D., Escobar J.A., Madrid E.M. Oxidative stress is closely related to clinical severity of pre-eclampsia. Biol. Res. 2006, 39:229-236.
16. Chapple S.J., Siow R.C., Mann G.E. Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging. Int. J. Biochem. Cell Biol. 2012, 44:1315-1320.
17. Chigusa Y., Tatsumi K., Kondoh E., Fujita K., Nishimura F., Mogami H., Konishi I. Decreased lectin-like oxidized LDL receptor 1 (LOX-1) and low Nrf2 activation in placenta are involved in preeclampsia. J. Clin. Endocrinol. Metab. 2012, 97:E1862-E1870.
18. Cudmore M., Ahmad S., Al-Ani B., Fujisawa T., Coxall H., Chudasama K., Devey L.R., Wigmore S.J., Abbas A., Hewett P.W., Ahmed A. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007, 115:1789-1797.
19. Cudmore M., Ahmad S., Al-Ani B., Hewett P., Ahmed S., Ahmed A. VEGF-E activates endothelial nitric oxide synthase to induce angiogenesis via cGMP and PKG-independent pathways. Biochem. Biophys. Res. Commun. 2006, 345:1275-1282.
20. Cullinan S.B., Zhang D., Hannink M., Arvisais E., Kaufman R.J., Diehl J.A. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol. Cell. Biol. 2003, 23:7198-7209.
21. Deng Y.M., Wu B.J., Witting P.K., Stocker R. Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. Circulation 2004, 110:1855-1860.
22. Dinkova-Kostova A.T., Holtzclaw W.D., Wakabayashi N. Keap1, the sensor for electrophiles and oxidants that regulates the phase 2 response, is a zinc metalloprotein. Biochemistry 2005, 44:6889-6899.
23. Dreger H., Westphal K., Wilck N., Baumann G., Stangl V., Stangl K., Meiners S. Protection of vascular cells from oxidative stress by proteasome inhibition depends on Nrf2. Cardiovasc. Res. 2010, 85(2):395-403.
24. Dulak J., Deshane J., Jozkowicz A., Agarwal A. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 2008, 117:231-241.
25. Duley L. The global impact of pre-eclampsia and eclampsia. Semin. Perinatol. 2009, 33:130-137.
26. Fasshauer M., Waldeyer T., Seeger J., Schrey S., Ebert T., Kratzsch J., Lossner U., Bluher M., Stumvoll M., Faber R., Stepan H. Circulating high-molecular-weight adiponectin is upregulated in preeclampsia and is related to insulin sensitivity and renal function. Eur. J. Endocrinol. 2008, 158:197-201.
27. Favreau L.V., Pickett C.B. Transcriptional regulation of the rat NAD(P)H:quinone reductase gene. Characterization of a DNA-protein interaction at the antioxidant responsive element and induction by 12-O-tetradecanoylphorbol 13-acetate. J. Biol. Chem. 1993, 268:19875-19881.
28. Florczyk U., Jazwa A., Maleszewska M., Mendel M., Szade K., Kozakowska M., Grochot-Przeczek A., Viscardi M., Czauderna S., Bukowska-Strakova K., Kotlinowski J., Jozkowicz A., Loboda A., Dulak J. Nrf2 regulates angiogenesis: effect on endothelial cells, bone marrow-derived proangiogenic cells and hind limb ischemia. Antioxid. Redox Signal. 2013, 20:1693-1708.
29. Fragoulis A., Laufs J., Muller S., Soppa U., Siegl S., Reiss L.K., Tohidnezhad M., Rosen C., Tenbrock K., Varoga D., Lippross S., Pufe T., Wruck C.J. Sulforaphane has opposing effects on TNF-alpha stimulated and unstimulated synoviocytes. Arthritis Res. Ther. 2012, 14:R220.
30. Genest D.S., Falcao S., Gutkowska J., Lavoie J.L. Impact of exercise training on preeclampsia: potential preventive mechanisms. Hypertension 2012, 60:1104-1109.
31. George E.M., Arany M., Cockrell K., Storm M.V., Stec D.E., Granger J.P. Induction of heme oxygenase-1 attenuates sFlt-1-induced hypertension in pregnant rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 301:R1495-R1500.
32. George E.M., Granger J.P. Heme oxygenase in pregnancy and preeclampsia. Curr. Opin. Nephrol. Hypertens. 2013, 22:156-162.
33. George E.M., Hosick P.A., Stec D.E., Granger J.P. Heme oxygenase inhibition increases blood pressure in pregnant rats. Am. J. Hypertens. 2013, 26:924-930.
34. Gomez-Guzman M., Jimenez R., Sanchez M., Zarzuelo M.J., Galindo P., Quintela A.M., Lopez-Sepulveda R., Romero M., Tamargo J., Vargas F., Perez-Vizcaino F., Duarte J. Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension. Free Radic. Biol. Med. 2012, 52:70-79.
35. Goswami D., Tannetta D.S., Magee L.A., Fuchisawa A., Redman C.W., Sargent I.L., von Dadelszen P. Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta 2006, 27:56-61.
36. Grosser N., Hemmerle A., Berndt G., Erdmann K., Hinkelmann U., Schurger S., Wijayanti N., Immenschuh S., Schroder H. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic. Biol. Med. 2004, 37:2064-2071.
37. Guan S.P., Tee W., Ng D.S., Chan T.K., Peh H.Y., Ho W.E., Cheng C., Mak J.C., Wong W.S. Andrographolide protects against cigarette smoke-induced oxidative lung injury via augmentation of Nrf2 activity. Br. J. Pharmacol. 2013, 168:1707-1718.
38. Heiss E.H., Schachner D., Werner E.R., Dirsch V.M. Active NF-E2-related factor (Nrf2) contributes to keep endothelial NO synthase (eNOS) in the coupled state: role of reactive oxygen species (ROS), eNOS, and heme oxygenase (HO-1) levels. J. Biol. Chem. 2009, 284:31579-31586.
39. Hine C.M., Mitchell J.R. NRF2 and the phase II response in acute stress resistance induced by dietary restriction. J. Clin. Exp. Pathol. 2012, S4.
40. Hogberg U. The World Health Report 2005: "make every mother and child count" - including Africans. Scand. J. Public Health 2005, 33:409-411.
41. Houston M. Nutrition and nutraceutical supplements for the treatment of hypertension: Part I. J. Clin. Hypertens. 2013, 15:752-757.
42. Houston M. Nutrition and nutraceutical supplements for the treatment of hypertension: Part II. J. Clin. Hypertens. 2013, 15(11):845-851.
43. Howden R. Nrf2 and cardiovascular defense. Oxid. Med. Cell. Longev. 2013, 104308.
44. Huang H.C., Nguyen T., Pickett C.B. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J. Biol. Chem. 2002, 277:42769-42774.
45. Hubel C.A., Roberts J.M., Ferrell R.E. Association of pre-eclampsia with common coding sequence variations in the lipoprotein lipase gene. Clin. Genet. 1999, 56:289-296.
46. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008, 51:970-975.
47. Huppertz B. IFPA Award in Placentology Lecture: biology of the placental syncytiotrophoblast-myths and facts. Placenta 2010, 31(Suppl.):S75-S81.
48. Huppertz B., Frank H.G., Kingdom J.C., Reister F., Kaufmann P. Villous cytotrophoblast regulation of the syncytial apoptotic cascade in the human placenta. Histochem. Cell Biol. 1998, 110:495-508.
49. Huppertz B., Peeters L.L. Vascular biology in implantation and placentation. Angiogenesis 2005, 8:157-167.
50. Huppertz B., Weiss G., Moser G. Trophoblast invasion and oxygenation of the placenta: measurements versus presumptions. J. Reprod. Immunol. 2013, 101-102:74-79. Epub 2013 Jun 6. 10.1016/j.jri.2013.04.003.
51. Ishii T., Warabi E., Siow R.C., Mann G.E. Sequestosome1/p62: a regulator of redox-sensitive voltageactivated potassium channels, arterial remodeling, inflammation, and neurite outgrowth. Free Radic. Biol. Med. 2013, 65C:102-116.
52. Itoh K., Mimura J., Yamamoto M. Discovery of the negative regulator of Nrf2. Keap1: a historical overview. Antioxid. Redox Signal. 2010, 13:1665-1678.
53. Itoh K., Mochizuki M., Ishii Y., Ishii T., Shibata T., Kawamoto Y., Kelly V., Sekizawa K., Uchida K., Yamamoto M. Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2). Mol. Cell. Biol. 2004, 24:36-45.
54. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999, 13:76-86.
55. Jin Y.C., Gam S.C., Jung J.H., Hyun J.S., Chang K.C., Hyun J.S. Expression and activity of heme oxygenase-1 in artificially induced low-flow priapism in rat penile tissues. J. Sex. Med. 2008, 5:1876-1882.
56. Kang S.J., You A., Kwak M.K. Suppression of Nrf2 signaling by angiotensin II in murine renal epithelial cells. Arch. Pharmacal Res. 2011, 34:829-836.
57. Kansanen E., Kuosmanen S.M., Leinonen H., Levonen A.L. The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 2013, 1:45-49.
58. Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacool. Toxicol. 2007, 47:89-116.
59. Kim J.W., Lim S.C., Lee M.Y., Lee J.W., Oh W.K., Kim S.K., Kang K.W. Inhibition of neointimal formation by trans-resveratrol: role of phosphatidyl inositol 3-kinase-dependent Nrf2 activation in heme oxygenase-1 induction. Mol. Nutr. Food Res. 2010, 54:1497-1505.
60. Kim S.B., E.U., Ly P. Bardoxolone-methyl (CDDO-Me): an antioxidant, antiinflammatory modulator is a novel radiation countermeasure and mitigator. Proceedings of the 22nd Annual NASA Space Radiation Investigators' Workshop 2011.
61. Kobayashi M., Itoh K., Suzuki T., Osanai H., Nishikawa K., Katoh Y., Takagi Y., Yamamoto M. Identification of the interactive interface and phylogenic conservation of the Nrf2-Keap1 system. Genes Cells 2002, 7:807-820.
62. Kweider N., Fragoulis A., Rosen C., Pecks U., Rath W., Pufe T., Wruck C.J. Interplay between vascular endothelial growth factor (VEGF) and nuclear factor erythroid 2-related factor-2 (Nrf2): implications for preeclampsia. J. Biol. Chem. 2011, 286:42863-42872.
63. Kweider N., Huppertz B., Wruck C.J., Beckmann R., Rath W., Pufe T., Kadyrov M. A role for Nrf2 in redox signalling of the invasive extravillous trophoblast in severe early onset IUGR associated with preeclampsia. PLoS ONE 2012, 7:e47055.
64. Lee J.M., Chan K., Kan Y.W., Johnson J.A. Targeted disruption of Nrf2 causes regenerative immune-mediated hemolytic anemia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9751-9756.
65. Lee J.M., Li J., Johnson D.A., Stein T.D., Kraft A.D., Calkins M.J., Jakel R.J., Johnson J.A. Nrf2, a multi-organ protector?. FASEB J. 2005, 19:1061-1066.
66. Lee S., Seo J., Ryoo S., Cuong T.D., Min B.S., Lee J.H. Malabaricone C inhibits PDGF-induced proliferation and migration of aortic smooth muscle cells through induction of heme oxygenase-1. J. Cell. Biochem. 2012, 113:2866-2876.
67. Levytska K., Kingdom J., Baczyk D., Drewlo S. Heme oxygenase-1 in placental development and pathology. Placenta 2013, 34:291-298.
68. Li J., Zhang C., Xing Y., Janicki J.S., Yamamoto M., Wang X.L., Tang D.Q., Cui T. Up-regulation of p27(kip1) contributes to Nrf2-mediated protection against angiotensin II-induced cardiac hypertrophy. Cardiovasc. Res. 2011, 90:315-324.
69. Li Volti G., Galvano F., Scacco A., Vanella L., Murabito P., Gullo A., Biondi A., Gazzolo D., Vadala S. Anesthetics and natural heme oxygenase-1 inducers: waiting for carbon monoxide?. Ann. Surg. 2008, 247:712-713. (author reply 713-714).
70. Liu D.N., Fang Y., Wu L.R., Liu X.D., Li P., He Z.Y. Effect of the haeme oxygenase-1/endogenous carbon monoxide system on atherosclerotic plaque formation in rabbits. Cardiovasc. J. Afr. 2010, 21:257-262.
71. Liu M., Reddy N.M., Higbee E.M., Potteti H.R., Noel S., Racusen L., Kensler T.W., Sporn M.B., Reddy S.P., Rabb H. The Nrf2 triterpenoid activator. CDDO-imidazolide, protects kidneys from ischemia-reperfusion injury in mice. Kidney Int. 2013, 85(1):134-141. Epub 2013 Oct 2. 10.1038/ki.2013.357.
72. Loset M., Mundal S.B., Johnson M.P., Fenstad M.H., Freed K.A., Lian I.A., Eide I.P., Bjorge L., Blangero J., Moses E.K., Austgulen R. A transcriptional profile of the decidua in preeclampsia. Am. J. Obstet. Gynecol. 2011, 204. 84.e81-27.
73. Loverro G., Greco P., Capuano F., Carone D., Cormio G., Selvaggi L. Lipoperoxidation and antioxidant enzymes activity in pregnancy complicated with hypertension. Eur. J. Obstet. Gynecol. Reprod. Biol. 1996, 70:123-127.
74. Lyall F., Robson S.C., Bulmer J.N. Spiral artery remodeling and trophoblast invasion in preeclampsia and fetal growth restriction: relationship to clinical outcome. Hypertension 2013, 62(6):1046-1054. Epub 2013 Sep 23. 10.1161/HYPERTENSIONAHA.113.01892.
75. Maines M.D. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 1988, 2:2557-2568.
76. Mam V., Tanbe A.F., Vitali S.H., Arons E., Christou H.A., Khalil R.A. Impaired vasoconstriction and nitric oxide-mediated relaxation in pulmonary arteries of hypoxia- and monocrotaline-induced pulmonary hypertensive rats. J. Pharmacol. Exp. Ther. 2010, 332:455-462.
77. Mansego M.L., Solar Gde M., Alonso M.P., Martinez F., Saez G.T., Escudero J.C., Redon J., Chaves F.J. Polymorphisms of antioxidant enzymes, blood pressure and risk of hypertension. J. Hypertens. 2011, 29:492-500.
78. Martinez-Fierro M.L., Garza-Veloz I., Carrillo-Sanchez K., Martinez-Gaytan V., Cortes-Flores R., Ochoa-Torres M.A., Guerrero G.G., Rodriguez-Sanchez I.P., Cancela-Murrieta C.O., Zamudio-Osuna M., Badillo-Almaraz J.I., Castruita-De la Rosa C. Expression levels of seven candidate genes in human peripheral blood mononuclear cells and their association with preeclampsia. Hypertens. Pregnancy 2013, (Epub ahead of print).
79. Merchant A.A., Singh A., Matsui W., Biswal S. The redox-sensitive transcription factor Nrf2 regulates murine hematopoietic stem cell survival independently of ROS levels. Blood 2011, 118:6572-6579.
80. Miehe U., Neumaier-Wagner P., Kadyrov M., Goyal P., Alfer J., Rath W., Huppertz B. Concerted upregulation of CLP36 and smooth muscle actin protein expression in human endometrium during decidualization. Cells Tissues Organs 2005, 179:109-114.
81. Miranda Guisado M.L., Vallejo-Vaz A.J., Garcia Junco P.S., Jimenez Jimenez L., Garcia Morillo S., Muniz Grijalvo O., Alfaro Lara V., Villar Ortiz J., Pamies-Andreu E. Abnormal levels of antioxidant defenses in a large sample of patients with hypertensive disorders of pregnancy. Hypertens. Res. 2012, 35:274-278.
82. Mitsuishi Y., Motohashi H., Yamamoto M. The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front. Oncol. 2012, 2:200.
83. Monu S.R., Pesce P., Sodhi K., Boldrin M., Puri N., Fedorova L., Sacerdoti D., Peterson S.J., Abraham N.G., Kappas A. HO-1 induction improves the type-1 cardiorenal syndrome in mice with impaired angiotensin II-induced lymphocyte activation. Hypertension 2013, 62:310-316.
84. Murray A.J. Oxygen delivery and fetal-placental growth: beyond a question of supply and demand?. Placenta 2012, 33(Suppl. 2):e16-e22.
85. Myatt L., Cui X. Oxidative stress in the placenta. Histochem. Cell Biol. 2004, 122:369-382.
86. Nakamura M., Sekizawa A., Purwosunu Y., Okazaki S., Farina A., Wibowo N., Shimizu H., Okai T. Cellular mRNA expressions of anti-oxidant factors in the blood of preeclamptic women. Prenat. Diagn. 2009, 29:691-696.
87. Ndisang J.F., Mishra M. The heme oxygenase system selectively suppresses the proinflammatory macrophage M1 phenotype and potentiates insulin signaling in spontaneously hypertensive rats. Am. J. Hypertens. 2013, 26(9):1123-1131. Epub 2013 Jun 11. 10.1093/ajh/hpt082.
88. Ogura T., Tong K.I., Mio K., Maruyama Y., Kurokawa H., Sato C., Yamamoto M. Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2842-2847.
89. Osburn W.O., Kensler T.W. Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat. Res. 2008, 659:31-39.
90. Pimentel A.M., Pereira N.R., Costa C.A., Mann G.E., Cordeiro V.S., de Moura R.S., Brunini T.M., Mendes-Ribeiro A.C., Resende A.C. l-Arginine-nitric oxide pathway and oxidative stress in plasma and platelets of patients with pre-eclampsia. Hypertens. Res. 2013, 36:783-788.
91. Rangasamy T., Guo J., Mitzner W.A., Roman J., Singh A., Fryer A.D., Yamamoto M., Kensler T.W., Tuder R.M., Georas S.N., Biswal S. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J. Exp. Med. 2005, 202:47-59.
92. Redman C.W. Preeclampsia: a multi-stress disorder. Rev. Med. Interne 2011, 32(Suppl. 1):S41-S44.
93. Redman C.W., Sacks G.P., Sargent I.L. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am. J. Obstet. Gynecol. 1999, 180:499-506.
94. Redman C.W., Sargent I.L. Pre-eclampsia, the placenta and the maternal systemic inflammatory response-a review. Placenta 2003, 24(Suppl. A):S21-S27.
95. Roberts J.M., Bell M.J. If we know so much about preeclampsia, why haven't we cured the disease?. J. Reprod. Immunol. 2013, 99:1-9.
96. Roberts J.M., Hubel C.A. The two stage model of preeclampsia: variations on the theme. Placenta 2009, 30(Suppl. A):S32-S37.
97. Roberts J.M., Taylor R.N., Musci T.J., Rodgers G.M., Hubel C.A., McLaughlin M.K. Preeclampsia: an endothelial cell disorder. Am. J. Obstet. Gynecol. 1989, 161:1200-1204.
98. Rojas-Rivera J., Ortiz A., Egido J. Antioxidants in kidney diseases: the impact of bardoxolone methyl. Int. J. Nephrol. 2012, 321714.
99. Russo C., Olivieri O., Girelli D., Faccini G., Zenari M.L., Lombardi S., Corrocher R. Anti-oxidant status and lipid peroxidation in patients with essential hypertension. J. Hypertens. 1998, 16:1267-1271.
100. Ryter S.W., Alam J., Choi A.M. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol. Rev. 2006, 86:583-650.
101. Satoh T., McKercher S.R., Lipton S.A. Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. Free Radic. Biol. Med. 2013, 65c:645-657.
102. Schlembach D. Pre-eclampsia-still a disease of theories. Fukushima J. Med. Sci. 2003, 49:69-115.
103. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet 2005, 365:785-799.
104. Sies H. Role of reactive oxygen species in biological processes. Klin. Wochenschr. 1991, 69:965-968.
105. Silva D.M., Marreiro Ddo N., Moita Neto J.M., Brito J.A., Neta E.A., Matias J.P., Sampaio F.A., Nogueira Ndo N. Oxidative stress and immunological alteration in women with preeclampsia. Hypertens. Pregnancy 2013, 32:304-311.
106. Smith S.C., Guilbert L.J., Yui J., Baker P.N., Davidge S.T. The role of reactive nitrogen/oxygen intermediates in cytokine-induced trophoblast apoptosis. Placenta 1999, 20:309-315.
107. Steegers E.A., von Dadelszen P., Duvekot J.J., Pijnenborg R. Pre-eclampsia. Lancet 2010, 376:631-644.
108. Stepan H. Angiogenic factors and pre-eclampsia: an early marker is needed. Clin. Sci. 2009, 116:231-232.
109. Stepan H., Ebert T., Schrey S., Reisenbuchler C., Stein S., Lossner U., Bluher M., Stumvoll M., Kratzsch J., Faber R., Fasshauer M. Serum levels of angiopoietin-related growth factor are increased in preeclampsia. Am. J. Hypertens. 2009, 22:314-318.
110. Suzuki T., Motohashi H., Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol. Sci. 2013, 34:340-346.
111. Taguchi K., Motohashi H., Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011, 16:123-140.
112. Telang M.A., Bhutkar S.P., Hirwani R.R. Analysis of patents on preeclampsia detection and diagnosis: a perspective. Placenta 2013, 34:2-8.
113. Tenhunen R., Marver H.S., Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc. Natl. Acad. Sci. U. S. A. 1968, 61:748-755.
114. Thimmulappa R.K., Lee H., Rangasamy T., Reddy S.P., Yamamoto M., Kensler T.W., Biswal S. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J. Clin. Invest. 2006, 116:984-995.
115. Toescu V., Nuttall S.L., Martin U., Kendall M.J., Dunne F. Oxidative stress and normal pregnancy. Clin. Endocrinol. (Oxf.) 2002, 57:609-613.
116. Tong K.I., Katoh Y., Kusunoki H., Itoh K., Tanaka T., Yamamoto M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol. Cell. Biol. 2006, 26:2887-2900.
117. Valcarcel-Ares M.N., Gautam T., Warrington J.P., Bailey-Downs L., Sosnowska D., de Cabo R., Losonczy G., Sonntag W.E., Ungvari Z., Csiszar A. Disruption of Nrf2 signaling impairs angiogenic capacity of endothelial cells: implications for microvascular aging. J. Gerontol. Ser. A: Biol. Sci. Med. Sci. 2012, 67:821-829.
118. van Rijn B.B., Nijdam M.E., Bruinse H.W., Roest M., Uiterwaal C.S., Grobbee D.E., Bots M.L., Franx A. Cardiovascular disease risk factors in women with a history of early-onset preeclampsia. Obstet. Gynecol. 2013, 121:1040-1048.
119. Verlohren S., Herraiz I., Lapaire O., Schlembach D., Moertl M., Zeisler H., Calda P., Holzgreve W., Galindo A., Engels T., Denk B., Stepan H. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am. J. Obstet. Gynecol. 2012, 206. 58 e51-e58.
120. Voelkel N.F., Bogaard H.J., Al Husseini A., Farkas L., Gomez-Arroyo J., Natarajan R. Antioxidants for the treatment of patients with severe angioproliferative pulmonary hypertension?. Antioxid. Redox Signal. 2013, 18:1810-1817.
121. Wakabayashi N., Slocum S.L., Skoko J.J., Shin S., Kensler T.W. When NRF2 talks, who's listening?. Antioxid. Redox Signal. 2010, 13:1649-1663.
122. Wild A.C., Moinova H.R., Mulcahy R.T. Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2. J. Biol. Chem. 1999, 274:33627-33636.
123. Wruck C.J., Claussen M., Fuhrmann G., Romer L., Schulz A., Pufe T., Waetzig V., Peipp M., Herdegen T., Gotz M.E. Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway. J. Neural Transm. Suppl. 2007, 57-67.
124. Wruck C.J., Fragoulis A., Gurzynski A., Brandenburg L.O., Kan Y.W., Chan K., Hassenpflug J., Freitag-Wolf S., Varoga D., Lippross S., Pufe T. Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice. Ann. Rheum. Dis. 2011, 70:844-850.
125. Wruck C.J., Gotz M.E., Herdegen T., Varoga D., Brandenburg L.O., Pufe T. Kavalactones protect neural cells against amyloid beta peptide-induced neurotoxicity via extracellular signal-regulated kinase 1/2-dependent nuclear factor erythroid 2-related factor 2 activation. Mol. Pharmacol. 2008, 73:1785-1795.
126. Wruck C.J., Huppertz B., Bose P., Brandenburg L.O., Pufe T., Kadyrov M. Role of a fetal defence mechanism against oxidative stress in the aetiology of preeclampsia. Histopathology 2009, 55:102-106.
127. Wruck C.J., Wruck A., Brandenburg L.O., Kadyrov M., Tohidnezhad M., Pufe T. Impact of Nrf2 on esophagus epithelium cornification. Int. J. Dermatol. 2011, 50:1362-1365.
128. Wu L., Juurlink B.H. The impaired glutathione system and its up-regulation by sulforaphane in vascular smooth muscle cells from spontaneously hypertensive rats. J. Hypertens. 2001, 19:1819-1825.
129. Yinon Y., Kingdom J.C., Odutayo A., Moineddin R., Drewlo S., Lai V., Cherney D.Z., Hladunewich M.A. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation 2010, 122:1846-1853.
130. Zhang D.D., Lo S.C., Cross J.V., Templeton D.J., Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell. Biol. 2004, 24:10941-10953.
131. Zhao H., Wong R.J., Kalish F.S., Nayak N.R., Stevenson D.K. Effect of heme oxygenase-1 deficiency on placental development. Placenta 2009, 30:861-868.
132. Zipper L.M., Mulcahy R.T. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J. Biol. Chem. 2002, 277:36544-36552.